Studies Show Breakthroughs in Male Contraception, Including First Male Contraceptive Hydrogel
By GlobeNewswire Published on April 26, 2025, 20:00 IST
LAS VEGAS, April 26, 2025 (GLOBE NEWSWIRE) — Groundbreaking research presented at the American Urological Association (AUA) Annual Meeting in Las Vegas is ushering in a new era for men's reproductive health.
Among this year's highlights are the initial safety results from the first-in-human trial of ADAM™, an innovative hydrogel developed as a reversible, non-hormonal male contraceptive. Additionally, new findings reveal that GLP1-agonist medications, commonly used for weight management and diabetes, are associated with improved sperm counts in overweight and obese men. Together, these studies represent significant advances in both male contraception and fertility, offering hope for expanded options and improved outcomes for men worldwide.
Researchers will present their study findings covering important updates on fertility and contraception from April 26 to 29. Raevti Bole, MD, a men's health urology specialist at the Cleveland Clinic, posed in-depth questions to the abstract authors, providing key insights into their research.
'These exciting studies presented at AUA2025 reflect new possibilities in male fertility and contraception research,' Dr. Bole said. 'For the first time, we're seeing promising safety results from a reversible, non-hormonal male birth control that may fit the needs of couples who need a secure contraceptive option but are not ready for something permanent. There is also some new evidence that GLP1 agonists could have additional benefits for fertility in men who are taking the medication for weight or diabetes management. Together, these findings may represent novel paths towards men's reproductive health and safe, effective family planning.'
The following abstracts are spotlighted in the AUA Press Program:
A recording of the key findings from the abstract authors is available to all press registrants. Fill out the registration form on the website to be added to the virtual programming: https://www.auanet.org/AUA2025/register/press-registration
NOTE TO REPORTERS: Presenting authors and moderators are available to discuss their findings. To arrange an interview with an expert, please contact the AUA Communications Team at [email protected].
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 26,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai
Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035" report has been added to world revenue for the AI-Enabled Drug Discovery and Clinical Trials Market will surpass US$3.00 billion in 2025 with strong revenue growth projected through to 2035. The report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new Drug Development Timelines and Cost Efficiency Driving Market GrowthKey drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms-such as generative models for molecular design and predictive analytics for patient recruitment-are expected to further boost market growth. However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these and Data Integration Challenges to Hamper Market GrowthWhile the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical Questions Answered How is the AI-enabled drug discovery and clinical trials market evolving? What is driving and restraining the AI-enabled drug discovery and clinical trials market? How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035? How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035? What will be the main driver for the overall market from 2025 to 2035? Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035? Who are the leading players and what are their prospects over the forecast period? What are the AI-enabled drug discovery and clinical trials projects for these leading companies? How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years? Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market? Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market? What are the best investment options for new product and service lines? What are the key prospects for moving companies into a new growth path and C-suite? Recent Developments On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets. On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs. On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes. Leading Companies Profiled AiCure Aitia Atomwise Inc. BenevolentAI Insilico Medicine PathAI, Inc. Recursion Saama Technologies Schroedinger, Inc. Tempus Inc. Key Topics Covered: 1 Report Overview1.1 Objectives of the Study1.2 Introduction to AI-Enabled Drug Discovery and Clinical Trials Market1.3 What This Report Delivers1.4 Why You Should Read This Report1.5 Key Questions Answered by This Analytical Report1.6 Who is This Report for?1.7 Methodology1.8 Frequently Asked Questions (FAQs)1.9 Associated Reports1.10 About the Publisher2 Executive Summary3 Market Overview3.1 Key Findings3.2 Market Dynamics3.3 Impact Analysis3.3.1 Market Driving Factors3.3.1.1 Growing Focus on Personalized Medicine3.3.1.2 Advancements in Technology3.3.1.3 Growing Adoption of AI in Healthcare3.3.2 Market Restraining Factors3.3.2.1 Limited Data Availability and Quality3.3.2.2 Integration with Existing Infrastructure3.3.2.3 Concerns over Data Privacy and Security3.3.3 Market Opportunities3.3.3.1 Improved Patient Outcomes3.3.3.2 Increasing AI adoption in Pharma and Biopharma Clinical Trials3.3.3.3 Growing Collaborations and Partnerships3.4 Regulatory Framework3.5 Emerging Markets and Megatrends3.6 Porter's Five Forces Analysis3.7 PEST Analysis4 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Component4.1 Key Findings4.2 Component Segment: Market Attractiveness Index4.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component4.4 Services4.4.1 Market Size by Region, 2025-2035 (US$ Million)4.4.2 Market Share by Region, 2025 & 2035 (%)4.5 Software Solutions5 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Application5.1 Key Findings5.2 Application Segment: Market Attractiveness Index5.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application5.4 Clinical Trials5.4.1 Market Size by Region, 2025-2035 (US$ Million)5.4.2 Market Share by Region, 2025 & 2035 (%)5.5 Drug Design5.6 Data Aggregation and Analysis5.7 Drug Characterization5.8 Biomarker Research5.9 Others6 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Therapeutic Area6.1 Key Findings6.2 Therapeutic Area Segment: Market Attractiveness Index6.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area6.4 Oncology6.4.1 Market Size by Region, 2025-2035 (US$ Million)6.4.2 Market Share by Region, 2025 & 2035 (%)6.5 Cardiovascular Diseases6.6 Infectious Diseases6.7 Neurodegenerative Diseases6.8 Metabolic Diseases6.9 Immunological Disorders6.10 Others7 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by End-users7.1 Key Findings7.2 End-users Segment: Market Attractiveness Index7.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users7.4 Pharmaceutical & Biopharmaceutical Companies7.4.1 Market Size by Region, 2025-2035 (US$ Million)7.4.2 Market Share by Region, 2025 & 2035 (%)7.5 Contract Research Organizations (CROs)7.6 Academic Institutes and Research Centre8 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Region8.1 Key Findings8.2 Regional Market Size Estimation and Forecast For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Meishan Emerges as a New Hub for the Satellite Industry: Global Experts Gather at the 3rd Meishan Satellite Application Industry Development Conference
CHENGDU, China, June 09, 2025 (GLOBE NEWSWIRE) -- On June 9, the 3 rd Meishan Satellite Application Industry Development Conference officially opened in Meishan City, Sichuan Province, China. Experts in remote sensing technology, aerospace, and related fields, along with representatives from international cooperation organizations, gathered in Meishan for an in-depth discussion on technological innovation, coordinated industrial chain development, and international cooperation models in the satellite industry, contributing insights and suggestions to help advance Meishan's satellite sector to a higher level. A Media Snippet accompanying this announcement is available in this link. The conference was sponsored by the China Association of Remote Sensing Application and the People's Government of Meishan City, organized by the Meishan Management Committee of Sichuan Tianfu New Area, and co-organized by Meishan Tianfu New Area Xingchan Investment Group Co., Ltd. At the opening ceremony, the China Association of Remote Sensing Application released the 2025 Blue Book on the Development of China's Remote Sensing Application Sector. Keynote speeches were delivered by Li Deren, photogrammetry and remote sensing scientist and professor at Wuhan University; Zhu Ninghua, microwave photonics expert and director of the Institute of Intelligent Photonics at Nankai University; and Xu Ying, Beidou navigation system scientist and researcher at the Aerospace Information Research Institute of the Chinese Academy of Sciences. Huantian Wisdom Technology Co., Ltd., the leading enterprise in Meishan's satellite industry, unveiled its platform "StarView Horizon", which integrates over 40 core spatiotemporal algorithms at the opening ceremony. It also signed cooperation agreements with Kazakhstan Temir Zholy, Kazakhstan Kazaerospace, and Malaysian Karuna Group for promoting satellite application projects. In the past three decades, China's space industry has rapidly advanced. As a result, numerous cities known for their related industries have popped up across the country. In the realm of satellite technology, regions beyond traditional strongholds like Beijing, Shanghai, and Xi'an are now making significant strides in this sector, cities such as Meishan have emerged as new hubs for the satellite industry. In recent years, Meishan City has seized the opportunity of commercial aerospace development, taking the lead in laying out the satellite application industry in Sichuan Province, and promoting the application of satellite remote sensing data in high-standard farmland, disaster prevention and reduction, resource survey, environmental protection, smart cities, and other fields. At present, Meishan has become the city with the largest number of commercial remote sensing satellites in Southwest China, ranking fourth in the country overall. Meishan unveiled its satellite industry development plan (2024-2030) last year, outlining a strategic roadmap to build a globally competitive satellite industry cluster by 2030, targeting an industrial scale exceeding 10 billion yuan (about 1.39 billion U.S. dollars). To achieve this ambitious goal, Meishan is actively advancing the development of key industrial projects. On December 30, 2024, the Western China Satellite Industrial Park, located in Meishan Tianfu New Area, officially began full operations. During this conference, nine new enterprises signed agreements to join the park, and one new science and technology innovation platform was introduced. To date, the park has attracted a total of 26 satellite-related enterprises and five scientific research platforms. By 2028, the scale of Meishan's satellite industry is expected to exceed 5 billion yuan. On the other side, the Huantian Cloud Smart Computing Center -- the largest data center dedicated to the commercial satellite sector in Southwest China -- is about to be put into operation. It aims to address three major bottlenecks hindering the development of the sector: insufficient computing power, limited storage capacity, and low application efficiency. "It is expected to complete the last piece of Meishan's aerospace industry layout, making the city one of the few places in China with comprehensive capabilities in satellite research and development, monitoring and control, application, and data transmission," Yang Zhenyu, deputy general manager of the Huantian Wisdom Technology Co., Ltd., owner of the new infrastructure, said. Source: The Meishan Management Committee of Sichuan Tianfu New Area CONTACT: Contact person: Ms. Hou, Tel: in to access your portfolio
Yahoo
4 hours ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
